By Timothy S. Donahue

Top Takeaways:

• The FDA’ Center for Tobacco Products (CTP) receives $712 million in annual funding, maintaining its current budget level.
• Approximately $200 million is earmarked for e-cigarette enforcement, including authority to detain and destroy illicit imports at ports of entry.
• Enhanced oversight comes via statutory authority to report to Congress on tobacco activities and interagency collaboration, including a $2 million task force with DOJ and DHS.

In the Senate’s Fiscal Year 2026 Agriculture‑FDA appropriations package, funding for tobacco control remains a central pillar. While the overall U.S. Food and Drug Administration’s budget holds at around $7 billion, Congress has maintained a central focus on the Center for Tobacco Products (CTP), which continues to receive $712 million, mirroring its allocation since 2019.

The funding bill, which has just passed through the Senate Appropriations Committee, continues to support the agency’s dual focus on scientific research and regulatory enforcement, two pillars of the agency’s tobacco control efforts. However, this year, the budget allocates an unprecedented $200 million specifically to combat the sale of unauthorized vaping products.

Established under the 2009 Family Smoking Prevention and Tobacco Control Act, the CTP plays a central role in reviewing premarket applications, inspecting retailers, and monitoring product sales across the country. What distinguishes this year’s Senate bill is the expanded emphasis on enforcement.

The legislation includes language authorizing the FDA to ramp up its crackdown on illegal nicotine products, especially unapproved disposable vapes that continue to flood the U.S. market. The $200 million earmarked for enforcement marks a dramatic increase in funding intended to address what officials and health advocates describe as a runaway illicit market.

Among the most consequential provisions is the new authority granted to FDA Commissioner Robert Califf to detain and destroy illegal e-cigarette products seized at ports of entry. Until now, the FDA had limited tools to stop noncompliant vapes from entering the country.

This change represents what many see as a generational shift in the agency’s enforcement posture. “This is a significant step forward,” said Harold Wimmer, president and CEO of the American Lung Association (ALA), which has long called for stronger federal action against unauthorized tobacco products.

The rise in illegal flavored and disposable vapes, many of which are manufactured overseas, has posed major enforcement challenges for the FDA. Public health advocates argue that while the funding boost is encouraging, the sheer scale of the illicit market—estimated in the billions—requires more comprehensive solutions, including faster product reviews and tighter coordination among federal agencies.

The bill also creates a new $2 million interagency task force, bringing together the FDA, Department of Justice (DOJ), and Department of Homeland Security (DHS). The task force aims to improve the detection, tracking, and interdiction of unauthorized nicotine products, particularly at border crossings and distribution hubs.

While details about the task force’s structure and operational strategy have not been released, lawmakers hope the initiative will close existing enforcement gaps and accelerate the removal of illegal products from circulation.

Within the CTP, the Office of Science employs more than 500 staffers conducting studies like the Population Assessment of Tobacco and Health (PATH) survey, which provides essential data on tobacco use and health outcomes. The Office of Compliance and Enforcement, with nearly 300 personnel and additional regulatory agents, oversees retailer inspections and enforcement against violators.

Under the new bill, manufacturers and retailers now face a heightened risk of penalties, seizures, or market removals if their products do not meet FDA requirements. The new port seizure authority and the task force are widely viewed as long-overdue responses to systemic challenges.

Yet experts caution that implementation will take time. Seizing and destroying noncompliant products at the border will require rulemaking, staff training, and collaboration with U.S. Customs and Border Protection. Similarly, the success of the interagency task force depends on clear communication protocols, data-sharing infrastructure, and strong leadership—elements that are not detailed in the public version of the bill.

Meanwhile, the nicotine industry remains in a state of cautious adaptation. While some companies have welcomed the increased oversight, others worry about unintended consequences or delays in product approvals. Advocacy groups continue to call for more funding and clearer regulatory pathways, particularly for smaller firms without the legal and financial resources of the major tobacco companies.

The Senate bill now heads to conference with the House of Representatives, which proposed a similar FDA budget structure that combines $3.2 billion in discretionary funding with $3.6 billion in user fees. The final legislation could include adjustments to the CTP’s funding or shift enforcement priorities further, depending on negotiations, according to sources with knowledge of the bills.

The challenge now is execution. The FDA must demonstrate that it can use the new funding and authority effectively. It has yet to show it has that ability.